MY ACCOUNT | NEWSLETTER |

IFF Launches PureStrong™, a Probiotic Made Specifically for Dogs


IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients and health & biosciences—is introducing PureStrong™, a new probiotic developed exclusively for canine digestive health.

Today, many people consider their pet dogs part of the family. This shift is fueling rapid growth in the $3.2 billion U.S. pet supplement market. With nearly half of U.S. pet owners having purchased or considering probiotics for their dogs, PureStrong™ sets a new standard: pet‑first science built specifically for canine biology.

“PureStrong™ is sourced directly from the microbiome of healthy canines and designed to support how dogs actually live—how they eat, travel, age and adapt to change,” said Allyson Fish, senior vice president of health sciences for IFF. “That’s how IFF leads pet wellness: science-driven innovation that performs in the real world.”

This unique probiotic for dogs is part of HOWARU® Pet, IFF’s portfolio of canine and feline-specific probiotic strains backed by microbiome science, quality manufacturing and clinical evaluation. With decades of leadership in probiotics and bioscience, IFF is helping pet health brands move beyond trend-driven formulations toward precision wellness.

Built for dogs, not repurposed for them

Unlike many probiotics on the market today, PureStrong™ is built around one targeted strain of Limosilactobacillus reuteri, rather than blends of generic strains originally developed for humans or livestock. Because this strain comes directly from the canine microbiome, it is naturally equipped to survive, attach and compete in a dog’s gut. This focused, single-strain approach allows pet supplement brands to create low-dose, highly targeted products without unnecessary complexity, delivering effective support that aligns with the biological needs of dogs. The strain is designed for the formats pet parents already trust—including powders, capsules, tablets and sticks—while giving brands a clear point of differentiation in one of the fastest-growing categories in pet care.

Why this matters for dog owners

Digestive health affects nearly every part of a dog’s daily life from comfort and hydration to nutrient absorption and immune health.

Diet changes, travel, stress and aging can all disrupt a dog’s gut, often showing up in ways pet parents notice immediately, like stool quality and digestive upset. PureStrong™ is designed to support dogs through everyday moments that can challenge digestive health. In a controlled study of healthy dogs undergoing an abrupt diet change, dogs receiving PureStrong™ showed improved markers of digestive health and hydration and diet tolerance, resulting in firmer stools without constipation.

“Dogs experience change just like we do from new food to new environments to new stages of life,” said Danielle Rendina, senior scientist for IFF Pet Health. “PureStrong™ works with a dog’s natural microbiome to support digestion gently and effectively, helping pet parents care for their dogs in a way that feels informed, intentional and personal.”

PureStrong™ delivers a clear and reassuring message to dog owners: this probiotic is made for dogs, powered by science, and supported by a company with deep microbiome expertise. This new probiotic for dogs reflects a broader evolution in pet care—one where dogs are treated with the same thoughtfulness, rigor and respect as the people who love them. 

Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love—advancing wellness, delighting the senses and enhancing the human experience.


Source: www.iff.com

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Legacy fuels UWVC leadership in comprehensive cancer care

Like0
Dislike0

DNA My Dog Expands Product Suite With Launch of New Health and Trait Test, Building on 18-Year Foundation in Canine Genetic Testing

Like0
Dislike0

From companion animals to patients interspecies lessons in neuroendocrine oncology.

Like0
Dislike0

Clinical signs, management, and survival of 278 dogs diagnosed with insulinoma under primary veterinary care in the United Kingdom.

Like0
Dislike0

Comparative evaluation of a novel phytochemical mixture and monensin on host- and pathogen-targeted strategies in broiler chickens challenged with Eimeria maxima.

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2026 - All Rights Reserved
ISSN 2768-198X

Top